NO122991B - - Google Patents
Download PDFInfo
- Publication number
- NO122991B NO122991B NO168449A NO16844967A NO122991B NO 122991 B NO122991 B NO 122991B NO 168449 A NO168449 A NO 168449A NO 16844967 A NO16844967 A NO 16844967A NO 122991 B NO122991 B NO 122991B
- Authority
- NO
- Norway
- Prior art keywords
- agent
- spermicidal
- blunted
- solution
- oil
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 230000001150 spermicidal effect Effects 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- -1 natural oils Chemical class 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical group CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical group CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Fremgangsmåte for fremstilling av kjemisk preparat. Procedure for the production of a chemical preparation.
Foreliggende oppfinnelse vedrører nye forbindelser som hovedsakelig skal anven-des på slimhinnen av vaginalfordypningen hvor de virker som spermisider. The present invention relates to new compounds which are mainly to be used on the mucous membrane of the vaginal cavity where they act as spermicides.
En rekke forskjellige spermisider, slik A number of different spermicides, such
som de i U.S. patent 2.330.846 og 2.541.103 angitte spermisid virkende forbindelser er allerede kjent tidligere. De spermiside forbindelser ifølge disse patenter omfatter i det vesentlige et vanlig bæremiddel i form av en gel som inneholder en umettet fettsyre med ti eller flere kullstoffatomer, f. eks. risinolsyre, oleinsyre og linoljesyre og et middel som minsker overflatespenning, f. eks. umettede fettsyrer og alkoholer og deres salter og estre samt en vannoppløse-lig alkylfenoksyetanol med følgende generelle formel: like those in the U.S. patent 2,330,846 and 2,541,103 specified spermicide active compounds are already known previously. The spermicidal compounds according to these patents essentially comprise a common carrier in the form of a gel containing an unsaturated fatty acid with ten or more carbon atoms, e.g. ricinoleic acid, oleic acid and linoleic acid and an agent that reduces surface tension, e.g. unsaturated fatty acids and alcohols and their salts and esters as well as a water-soluble alkylphenoxyethanol with the following general formula:
hvor R er en alkylradikal, fortrinsvis i pa-rastilling til surstoffatomet og x er 1 eller større enn 1. Alkylfenoksyetanolen kan også være tilstede i form av en blanding og x i den foretrukne form har en verdi av fra 9.25 til 10.25 og en gjennom-snittlig molekylvekt av 959 til 639. where R is an alkyl radical, preferably in para-position to the oxygen atom and x is 1 or greater than 1. The alkylphenoxyethanol can also be present in the form of a mixture and x in the preferred form has a value of from 9.25 to 10.25 and an average molecular weight of 959 to 639.
Det har vært uttalt at spermiside forbindelser fortrinsvis skal avstumpes ved en sur pH-verdi, fordi de fleste spermiside forbindelser og særlig disse forbindelser hvis spermiside virkning baserer seg på overflateaktive midler og på høyere umettede fettsyrer blir mere effektive og har en sterkere spermisid virkning når de er avstumpet ved en pH av 4 til 6 med et surt avstumpesystem. Selvom spermiside forbindelser avstumpet ved en pH innenfor det ovennevnte område har vært meget i bruk, er det funnet at de resulterer i at der uønsket ofte forekommer irritasjoner av de vaginale slimhinner. På grunn av den uønskete irritasjon frembrakt av de spermiside forbindelser av ovennevnte type som er avstumpet med et surt avstumpesystem har man i lang tid ønsket å skaffe en spermisid forbin-delse som er meget effektiv såvel ved pH av nakkeslim som normalt er mellom ca. 7 til 7,5 som ved pH av sedvæsken som er ca. 7.7 med andre ord var det ønsket å skaffe spermiside forbindelser som var meget effektive ved pH-verdier fra svakt ba-siske til svakt sure for derved å bringe irritasjon av de vaginale slimhinner til et mi-nimum. It has been stated that spermicidal compounds should preferably be blunted at an acidic pH value, because most spermicidal compounds and especially those compounds whose spermicidal action is based on surfactants and on higher unsaturated fatty acids become more effective and have a stronger spermicidal effect when they is blunted at a pH of 4 to 6 with an acidic blunting system. Although spermicidal compounds blunted at a pH within the above-mentioned range have been widely used, it has been found that they result in undesirable frequent irritations of the vaginal mucous membranes. Due to the unwanted irritation produced by the spermicidal compounds of the above type which are blunted with an acidic blunting system, it has long been desired to obtain a spermicidal compound which is very effective both at the pH of cervical mucus which is normally between approx. 7 to 7.5 as with the pH of the seminal fluid which is approx. 7.7 in other words, it was desired to obtain spermicidal compounds which were very effective at pH values from slightly basic to slightly acidic in order to thereby bring irritation of the vaginal mucous membranes to a minimum.
Det er nå funnet at en spermisid for-bindelse med stor effektivitet ved en pH-verdi fra ca. 6.8 til ca. 8.6 kan skaffes ved å inkorporere i en olje i vann-emulsjon en vannoppløselig alkylfenoksyetanol med følgende formel: It has now been found that a spermicidal compound with great efficiency at a pH value from approx. 6.8 to approx. 8.6 can be obtained by incorporating into an oil-in-water emulsion a water-soluble alkylphenoxyethanol with the following formula:
hvor x har en verdi fra 6 til inklusiv 10 og hvor alkylgruppen er rettlinjet eller har en kjedef or grenet struktur, idet det først-nevnte er å foretrekke. Hvis x har en verdi under 6 og over 10, er den spermiside virkning av den ovennevnte alkylfenoksypolyetoksyetanol i vandig bæremedium betyde- where x has a value from 6 to 10 inclusive and where the alkyl group is linear or has a chain-branched structure, the former being preferred. If x has a value below 6 and above 10, the spermicidal effect of the above-mentioned alkylphenoxypolyethoxyethanol in an aqueous carrier medium means
lig minsket. Midler i henhold til oppfinnelsen forlanger ikke at det er tilstede høyere umettete fettsyrer for å gi dem høy spermisid effektivitet. body decreased. Agents according to the invention do not require higher unsaturated fatty acids to be present to give them high spermicidal effectiveness.
Det vandige bæremedium er en olje i vann-emulsjon. Naturlig forekommende fettsyrer, slik som stearin- og palmitinsyre og også fettstoffer, slik som glycerol mono-, di-, og tristearater og palmitater kan brukes i bæremidlene i form av olje i vann-emulsjoner. Syrene og glycerol estere kan brukes alene eller i kombinasjon med oljer og høyere alkoholer, slik som naturlige oljer, f. eks. jordnøttolje, sesamolje og liknende, og fettalkoholer f. eks. cetylstearyl og palmitylalkohol og liknende. Et fukte-middel, slik som glycerin, propylenglykol, sorbitol og liknende er fortrinsvis også tilstede i middelet. The aqueous carrier medium is an oil in water emulsion. Naturally occurring fatty acids, such as stearic and palmitic acid and also fatty substances, such as glycerol mono-, di- and tristearates and palmitates can be used in the carriers in the form of oil in water emulsions. The acids and glycerol esters can be used alone or in combination with oils and higher alcohols, such as natural oils, e.g. peanut oil, sesame oil and the like, and fatty alcohols, e.g. cetylstearyl and palmityl alcohol and the like. A wetting agent, such as glycerin, propylene glycol, sorbitol and the like is preferably also present in the agent.
Olje i vann-emulsjonen kan generelt fremstilles ved å sammensmelte de fettak-tige bestanddeler, slik som syrer, fettstoffer, fettalkoholer og naturlige oljer, ved å bringe temperaturen til ca. 60°—85° C og deretter å tilsette de smeltete bestanddeler langsomt og under god omrøring til en opp-løsning av de øvrige bestanddeler i vann, hvilken oppløsning også har en temperatur av 60 til 85° C. Etter at tilsettingen er fullstendig omrøres middelet i minst en time eller inntil det er avkjølt til romtemperatur. The oil in water emulsion can generally be produced by fusing the fatty components, such as acids, fatty substances, fatty alcohols and natural oils, by bringing the temperature to approx. 60°—85° C and then adding the melted ingredients slowly and with good stirring to a solution of the other ingredients in water, which solution also has a temperature of 60 to 85° C. After the addition is complete, the agent is stirred for at least one hour or until cooled to room temperature.
Mengden av alkylfenoksypolyetoksyetanol tilstede i de forskjellige bæremidler utgjør fortrinsvis ca. 5 vektprosent, men kan ligge innenfor området av fra 3 til 7 vektprosent. The amount of alkylphenoxypolyethoxyethanol present in the various carriers preferably amounts to approx. 5 percent by weight, but can lie within the range of from 3 to 7 percent by weight.
Foreliggende oppfinnelse angår således forbindelser med slike karakteristiske egen-skaper og med et slikt forhold mellom be-standdelene som eksempelvis angis i de etterfølgende utførelseseksempler. The present invention thus relates to compounds with such characteristic properties and with such a ratio between the constituents as, for example, is indicated in the following examples.
For å gjøre oppfinnelsen lettere for-ståelig angis det i det etterfølgende noen eksempler. Det vil imidlertid forståes at oppfinnelsen ikke er begrenset til disse de-taljerte eksempler som bare bedre skal illustrere oppfinnelsen. In order to make the invention easier to understand, some examples are given below. However, it will be understood that the invention is not limited to these detailed examples which are only intended to better illustrate the invention.
I de etterfølgende eksempler er alle deler vektsdeler. In the following examples, all parts are parts by weight.
Eksempel 1. Example 1.
■ Eksempel 2. ■ Example 2.
Middelet ifølge eks. 1 fremstilles ved å opphete en blanding av stearinsyre og cetylalkohol til 85° C og å tilsette det langsomt og under omrøring til en oppløsning av de øvrige bestanddeler i vann, som også har en temperatur av 85° C. Omrøringen fortsettes inntil middelet er avkjølt til værelsetemperatur. The means according to e.g. 1 is prepared by heating a mixture of stearic acid and cetyl alcohol to 85° C and adding it slowly and while stirring to a solution of the other ingredients in water, which also has a temperature of 85° C. Stirring is continued until the agent has cooled to room temperature.
Middelet ifølge eks. 2 fremstilles ved å opphete en blanding av glyceryl-monostea-rat og jordnøttolje til en temperatur av 85° C og å tilsette den langsomt og under omrøring til en oppløsning av de øvrige bestanddeler i vann, som også har en temperatur av 85° C. Omrøringen fortsettes inntil middelet er avkjølt til værelsetemperatur. The means according to e.g. 2 is prepared by heating a mixture of glyceryl monostearate and peanut oil to a temperature of 85°C and adding it slowly and while stirring to a solution of the other ingredients in water, which also has a temperature of 85°C. Stirring is continued until the agent has cooled to room temperature.
De spesifike spermiside forbindelser ifølge eksempel I og II ble undersøkt med hensyn til deres spermiside virkning etter følgende metode. The specific spermicidal compounds according to examples I and II were examined with regard to their spermicidal action according to the following method.
De spermiside forbindelser av eks. I og II ble fortynnet med en fysiologisk salt-oppløsning for å gi dem en konsentrasjon av en del av middelet til 150 deler saltopp-løsning, idet saltoppløsningen inneholdt 9 gr. NaCl pr. liter vann. De med saltoppløs-ningen fortynnete midler ble kraftig ristet for å danne en ensartet blanding. 1 cm<3> av hvert i saltoppløsningen fortynnet middel ble innført i et separat reagensglass som inneholdt 0.2 cm<3> fersk menneskesed. Inn-holdet ble grundig og fort blandet og i hvert tilfelle mikroskopisk undersøkt for å be-stemme bevegelsesevnen av spermatosoer. Blanding, anbringelse av prøven på objekt-glasset og den etterfølgende mikroskopiske undersøkelse tok maksimalt 20 sekunder. Ved alle undersøkelser var spermatosoene fullstendig ubevegelige ved den første un-dersøkelse under mikroskopet. Menneskesed brukt ved prøvene var fått ved å blande sammen sed fra tre givere og sedprøver ble tatt, samlet, avkjølt og brukt i løpet av noen få timer for å sikre at spermatosoene hadde full bevegelsesevne i forsøksøyeblikk. pH av midlene ifølge eks. I og II fortynnet i saltoppløsningen og blandet med menneskesed var 6.8 henholdsvis 7.4. The spermicidal compounds of e.g. I and II were diluted with a physiological salt solution to give them a concentration of one part of the agent to 150 parts of saline, the saline containing 9 gr. NaCl per liters of water. The agents diluted with the salt solution were vigorously shaken to form a uniform mixture. 1 cm<3> of each agent diluted in the saline solution was introduced into a separate test tube containing 0.2 cm<3> of fresh human semen. The contents were thoroughly and quickly mixed and in each case microscopically examined to determine the motility of spermatozoa. Mixing, placing the sample on the slide and the subsequent microscopic examination took a maximum of 20 seconds. In all examinations, the spermatozoa were completely immobile at the first examination under the microscope. Human semen used in the tests was obtained by mixing semen from three donors and semen samples were taken, collected, cooled and used within a few hours to ensure that the spermatozoa had full motility at the time of the test. pH of the agents according to e.g. I and II diluted in the salt solution and mixed with human semen were 6.8 and 7.4 respectively.
Midlene ifølge eks. I og II var mest effektive ved pH fra nesten nøytral til lett basisk. Deler av en fortynnet oppløsning av middelet ifølge eksempel I med et inn-hold av 1 del av middelet til 100 deler fysiologisk saltoppløsning ble avstumpet med et surt avstumpesystem ved en pH av 4.2, 6,0, 7,4, og 8,6. De forskjellige avstumpete opp-løsninger ble undersøkt for spermisid aktivitet på den ovenfor angitte måte. De avstumpete oppløsninger og sedblandinger hadde for oppløsninger avstumpet ved en pH av 4.2, 6.0, 7.4, og 8.6 en pH av 5.48, 6.5, 7.22 og henholdsvis 8.36. Det tok ett minutt og 15 sekunder til spermatosoene ble fullstendig ubevegelige når de var blandet med en oppløsning som var avstumpet ved en pH av 4.2, tre minutter når de var blandet med en oppløsning som var avstumpet ved en pH av 6.0, mindre enn 20 sekunder når de var blandet med en oppløsning avstumpet ved en pH av 7.4 og 40 sekunder når de var blandet med en oppløsning avstumpet ved en pH av 8.6. The funds according to e.g. I and II were most effective at pH from nearly neutral to slightly basic. Portions of a diluted solution of the agent according to example I with a content of 1 part of the agent to 100 parts of physiological saline were blunted with an acid blunting system at a pH of 4.2, 6.0, 7.4, and 8.6. The different blunted solutions were examined for spermicidal activity in the manner indicated above. The blunted solutions and seed mixtures had for solutions blunted at a pH of 4.2, 6.0, 7.4, and 8.6 a pH of 5.48, 6.5, 7.22 and 8.36 respectively. It took one minute and 15 seconds for the spermatozoa to become completely immobile when mixed with a solution blunted at a pH of 4.2, three minutes when mixed with a solution blunted at a pH of 6.0, less than 20 seconds when mixed with a solution blunted at a pH of 7.4 and 40 seconds when mixed with a solution blunted at a pH of 8.6.
Det ble fremstilt et middel svarende til eksempel I, unntatt at para-normal-nonyl-fenoksypolyetoksyetanol med 6 etoksygrupper var erstattet med para-tertiær oktyl-fenoksypolyetoksyetanol med i gjennom-snitt ca. 9.75 etoksygrupper. Dette middel hadde en pH av 5.5 og ble undersøkt for spermisid aktivitet på samme måte som ovenfor. De største fortynninger av dette middel som var istand til å gjøre spermatosoene ubevegelige i løpet av 20 sekunder inneholdt en del av middelet og 150 deler fysiologisk saltoppløsning når de var avstumpet ved en pH av 4,2, 1 del av middelet og 100 deler av fysiologisk saltoppløsning når de var avstumpet ved en pH av 6,0 1 del av middelet og 100 deler av fysiologisk salt-oppløsning når de var avstumpet ved en pH av 7.4 og 1 del av middelet og 80 deler av fysiologisk saltoppløsning når de var avstumpet ved en pH av 8.6. Middelet irri-terte de vaginale slimhinner og irritasjonen hendte så ofte at det var uønsket å bruke middelet ved behandling av vagina. Midlene ifølge eksempél I og II hadde ikke noen irriterende virkning på de vaginale slimhinner. An agent similar to example I was prepared, except that para-normal-nonyl-phenoxypolyethoxyethanol with 6 ethoxy groups was replaced with para-tertiary octyl-phenoxypolyethoxyethanol with an average of approx. 9.75 ethoxy groups. This agent had a pH of 5.5 and was tested for spermicidal activity in the same way as above. The largest dilutions of this agent capable of immobilizing spermatozoa within 20 seconds contained one part of the agent and 150 parts of physiological saline when blunted at a pH of 4.2, 1 part of the agent and 100 parts of physiological saline. saline when blunted at a pH of 6.0 1 part of agent and 100 parts of physiological saline when blunted at a pH of 7.4 and 1 part of agent and 80 parts of physiological saline when blunted at a pH of 8.6. The agent irritated the vaginal mucous membranes and the irritation happened so often that it was undesirable to use the agent when treating the vagina. The agents according to examples I and II had no irritating effect on the vaginal mucous membranes.
Det ble fremstilt et middel svarende til eksempel I, unntatt at para-normal-nonyl-fenoksypolyetoksyetanol med 6 etoksygrupper var erstattet med vann. Dette middel hadde en pH av 6.8 og ble undersøkt for spermisid aktivitet på den ovenfor angitte måte. En oppløsning som inneholdt 1 del av middelet og 5 deler av fysiologisk salt-oppløsning var ikke istand til å gjøre spermatosoene ubevegelige i løpet av tre timer. An agent similar to example I was prepared, except that para-normal-nonyl-phenoxypolyethoxyethanol with 6 ethoxy groups was replaced by water. This agent had a pH of 6.8 and was examined for spermicidal activity in the manner indicated above. A solution containing 1 part of the agent and 5 parts of physiological salt solution was unable to immobilize the spermatozoa within three hours.
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55517566A | 1966-06-03 | 1966-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO122991B true NO122991B (en) | 1971-09-13 |
Family
ID=24216259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO168449A NO122991B (en) | 1966-06-03 | 1967-06-02 |
Country Status (14)
Country | Link |
---|---|
US (1) | US3449314A (en) |
BE (1) | BE699251A (en) |
CH (1) | CH543886A (en) |
CS (1) | CS154570B2 (en) |
DE (1) | DE1617718A1 (en) |
DK (1) | DK114996B (en) |
ES (1) | ES341266A1 (en) |
FI (1) | FI47374C (en) |
GB (1) | GB1163493A (en) |
GR (1) | GR32294B (en) |
IL (1) | IL28058A (en) |
NL (1) | NL6707646A (en) |
NO (1) | NO122991B (en) |
SE (1) | SE331886C (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3916026A (en) * | 1968-09-19 | 1975-10-28 | Biotest Serum Institut Gmbh | Method for the preparation of gamma-globulin suitable for intravenous use |
DE2624373C2 (en) * | 1976-05-31 | 1983-02-03 | Arnold Dr. 8782 Karlstadt Seufert | Process for the production of sterile filtered cryoprecipitate with an enrichment of factor VIII |
US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
AU784808B2 (en) * | 2001-04-02 | 2006-06-29 | Kedrion Melville Inc. | Prion and viral clearance process |
WO2003100080A2 (en) * | 2002-05-23 | 2003-12-04 | Ortho-Clinical Diagnostics, Inc. | Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration |
AU2005229674B2 (en) * | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
US2770616A (en) * | 1951-01-29 | 1956-11-13 | Protein Foundation Inc | Fractionation of proteinaceous materials in blood plasma and liver tissue |
US2761808A (en) * | 1952-09-06 | 1956-09-04 | Ortho Pharma Corp | Plasma fractionation process |
US2761809A (en) * | 1954-07-22 | 1956-09-04 | Ortho Pharma Corp | Preparation of blood fraction for use in rh testing procedures |
US2761811A (en) * | 1954-07-22 | 1956-09-04 | Ortho Pharma Corp | Preparation of blood fraction for use in rh testing procedures |
US2761810A (en) * | 1954-07-22 | 1956-09-04 | Ortho Pharma Corp | Preparation of blood fraction for use in rh testing procedures |
US2790790A (en) * | 1954-11-10 | 1957-04-30 | Swift & Co | Protein fractionation |
US3361732A (en) * | 1964-07-28 | 1968-01-02 | Dow Chemical Co | Method for concentration of blood protein solutions employing methanol and flash evaporation |
-
1966
- 1966-06-03 US US555175A patent/US3449314A/en not_active Expired - Lifetime
-
1967
- 1967-05-29 IL IL28058A patent/IL28058A/en unknown
- 1967-05-30 DE DE19671617718 patent/DE1617718A1/de active Pending
- 1967-05-30 CH CH763667A patent/CH543886A/en not_active IP Right Cessation
- 1967-05-31 BE BE699251D patent/BE699251A/xx unknown
- 1967-05-31 GB GB25107/67A patent/GB1163493A/en not_active Expired
- 1967-06-01 ES ES341266A patent/ES341266A1/en not_active Expired
- 1967-06-01 NL NL6707646A patent/NL6707646A/xx unknown
- 1967-06-02 NO NO168449A patent/NO122991B/no unknown
- 1967-06-02 FI FI671561A patent/FI47374C/en active
- 1967-06-02 CS CS404867A patent/CS154570B2/cs unknown
- 1967-06-02 SE SE774067A patent/SE331886C/en unknown
- 1967-06-02 GR GR670132294A patent/GR32294B/en unknown
- 1967-06-02 DK DK288767AA patent/DK114996B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CH543886A (en) | 1973-11-15 |
SE331886C (en) | 1974-01-28 |
FI47374B (en) | 1973-07-31 |
IL28058A (en) | 1971-08-25 |
BE699251A (en) | 1967-11-30 |
US3449314A (en) | 1969-06-10 |
GB1163493A (en) | 1969-09-04 |
DK114996B (en) | 1969-08-25 |
ES341266A1 (en) | 1968-06-16 |
SE331886B (en) | 1971-01-18 |
CS154570B2 (en) | 1974-04-30 |
FI47374C (en) | 1973-11-12 |
NL6707646A (en) | 1967-12-04 |
GR32294B (en) | 1967-06-08 |
DE1617718A1 (en) | 1971-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oppenheimer et al. | Sarcomas induced in rats by implanting cellophane | |
Hoagland et al. | Revival of mammalian sperm after immersion in liquid nitrogen | |
Pappius et al. | Water and electrolyte content of cerebral tissues in experimentally induced edema | |
Rice | The carbohydrate matrix of the epithelial-cell inclusion in trachoma | |
US4602042A (en) | Contraceptive methods | |
NO122991B (en) | ||
Tosic et al. | Effect of egg-yolk and its constituents on the respiration and fertilizing capacity of spermatozoa | |
Mimura | On the Mechanism of Travel of Spermatozoa through the Oviduct in the Domestic Fowl, with Special Reference to the Artificial Insemination. | |
EP0009596A1 (en) | Aqueous lipid standard solution | |
Baker | The spermicidal powers of chemical contraceptives: II. Pure substances | |
Cross et al. | The effect of toxaemia on the metabolism of the liver. Diphtheritic toxaemia and carbohydrate synthesis | |
Just | Initiation of development in Nereis | |
White et al. | Breakdown of seminal glycerylphosphorylcholine by secretions of the female reproductive tract | |
Bell | The staining of fats in epithelium and muscle fibers | |
Menten | A study of the oxidase reaction with α-naphthol and paraphenylenediamine | |
Mettler | The Marchi method for demonstrating degenerated fiber connections within the central nervous system | |
LINDBLOM | On the effects of various iodized oils on the meninges | |
Mossman | The dioxan technic | |
Fish | The use of formalin in neurology | |
Levy | Experimental induction of tumor-like lesions of the notochord of fish | |
Manwell et al. | A modified method of preparing the JSB stain | |
Stewart | Renal concentrating ability in mice: a model for the use of genetic variation in elucidating relationships between structure and function | |
AT326278B (en) | HISTOLOGICAL FIXANT | |
KRAJIAN | A rapid method of staining Spirochaeta pallida in single sections of tissue | |
US2056779A (en) | Medicament for the treatment of burns |